Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+NSCLC Patients

被引：79

作者：

Kowanetz, Marcin ^{[1
]}

Zou, Wei ^{[1
]}

Shames, David ^{[1
]}

Cummings, Craig ^{[1
]}

Rizvi, Naiyer ^{[2
]}

Spira, Alexander ^{[3
,4
]}

Frampton, Garrett ^{[5
]}

Leveque, Vincent ^{[1
]}

Flynn, Susan ^{[1
]}

Mocci, Simonetta ^{[1
]}

Shankar, Geetha ^{[1
]}

Funke, Roel ^{[1
]}

Ballinger, Marcus ^{[1
]}

Waterkamp, Daniel ^{[1
]}

Chen, Daniel ^{[1
]}

Sandler, Alan ^{[1
]}

Hampton, Garret ^{[1
]}

Amler, Lukas ^{[1
]}

Hegde, Priti ^{[1
]}

Hellmann, Matthew ^{[6
]}

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

[2] Columbia Univ, New York, NY USA

[3] US Oncol Res, The Woodlands, TX USA

[4] Virginia Canc Specialists Res Inst, Fairfax, VA USA

[5] Fdn Med, Cambridge, MA USA

[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

关键词：

Immunotherapy; mutational load; NSCLC; Biomarkers;

D O I：

10.1016/j.jtho.2016.11.343

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA20.01

引用

页码：S321 / S322

页数：2